The place for eribulin in the treatment of metastatic breast cancer

Current Oncology Reports

Volumn 13, Issue 1, 2011, Pages 11-16

  Gradishar, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chemotherapy; Eribulin mesylate; Metastatic breast cancer; Microtubule dynamics inhibitor

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; CARBOPLATIN; CISPLATIN; EPOTHILONE DERIVATIVE; ERIBULIN; GEMCITABINE; IXABEPILONE; KETOCONAZOLE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; VINCA ALKALOID;

ARTICLE; ASTHENIA; BLADDER CANCER; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; DISTRIBUTION VOLUME; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HALICHONDRIA OKADAI; HEAD AND NECK CANCER; HUMAN; KIDNEY CLEARANCE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SOLID TUMOR; SPONGE (PORIFERA); UTERINE CERVIX CANCER;

ANIMALS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; FURANS; HUMANS; KETONES; MESYLATES; NEOPLASM METASTASIS; SURVIVAL; TREATMENT OUTCOME;

EID: 79551519944     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0145-9     Document Type: Article

References (30)

1. American Cancer Society: Cancer Facts and Figures 2010. Available at http://www.cancer.org/Research/CancerFactsFigures/BreastCancerFactsFigures/ breast-cancer-facts - figures-2009-2010. Accessed 2010.
2. • Beslija S, Bonneterre J, Burstein HJ, et al.: Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009, 20:1771-1785. This review outlines the most recent consensus by the Central European Cooperative Oncology Group on recommended treatment practices and clinical management of MBC, taking into account emerging treatment strategies, prognostic markers, and improved diagnostic techniques.
3. A Dufresne X Pivot C Tournigand, et al. 2008 Impact of chemotherapy beyond the first line in patients with metastatic breast cancer Breast Cancer Res Treat 107 275 279 1:CAS:528:DC%2BD2sXhsVarur3E 10.1007/s10549-007-9550-7 17380382 (Pubitemid 350265698)
4. A Moreno-Aspitia EA Perez 2009 Treatment options for breast cancer resistant to anthracycline and taxane Mayo Clin Proc 84 533 545 1:CAS:528:DC%2BD1MXnsVWqsrw%3D 10.4065/84.6.533 19483170
5. • National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology V.1.2010. Available at http://www.nccn.org/professionals/ physician-gls/PDF/breast.pdf. Accessed 30 Oct 2009. This report provides a substantial and thorough overview of the clinical practice guidelines for all stages of breast cancer as established by the US-based NCCN.
6. MA Jordan L Wilson 2004 Microtubules as a target for anticancer drugs Nat Rev Cancer 4 253 265 1:CAS:528:DC%2BD2cXis1Gmt74%3D 10.1038/nrc1317 15057285
7. F Cardoso E Senkus-Konefka L Fallowfield A Costa M Castiglione 2010 Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl 5 v15 v19 10.1093/annonc/mdq160 20555067
8. Cortazar P: Drug treatment of metastatic breast cancer: FDA approval overview. Available at www.fda.gov/ohrms/dockets/ac/07/slides/2007-4332s1-01- FDA-Cortazar.ppt. Accessed 2010.
9. SM Swain JC Arezzo 2008 Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management Clin Adv Hematol Oncol 6 455 467 18567992
10. DA Yardley 2010 Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents Clin Breast Cancer 10 64 73 1:CAS:528: DC%2BC3cXisFeqsb4%3D 10.3816/CBC.2010.n.009 20133261
11. ES Thomas 2008 Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 26 2223 10.1200/JCO.2008.16.5019 18445853
12. MJ Towle KA Salvato J Budrow, et al. 2001 In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B Cancer Res 61 1013 1021 1:CAS:528:DC%2BD3MXhsFSru7k%3D 11221827
13. G Kuznetsov MJ Towle H Cheng, et al. 2004 Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389 Cancer Res 64 5760 5766 1:CAS:528: DC%2BD2cXmslaksrw%3D 10.1158/0008-5472.CAN-04-1169 15313917 (Pubitemid 39095575)
14. MA Jordan K Kamath T Manna, et al. 2005 The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth Mol Cancer Ther 4 1086 1095 1:CAS:528:DC%2BD2MXmtFSltrY%3D 10.1158/1535-7163.MCT-04-0345 16020666 (Pubitemid 41079102)
15. T Okouneva O Azarenko L Wilson BA Littlefield MA Jordan 2008 Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase Mol Cancer Ther 7 2003 2011 1:CAS:528:DC%2BD1cXoslCgurg%3D 10.1158/1535-7163.MCT-08-0095 18645010
16. JA Smith L Wilson O Azarenko, et al. 2010 Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability Biochemistry 49 1331 1337 1:CAS:528:DC%2BC3cXnsVyntA%3D%3D 10.1021/bi901810u 20030375
17. JA Smith MA Jordan 2010 Determination of drug binding to microtubules in vitro Methods Cell Biol 95 289 299 1:CAS:528:DC%2BC3cXpvFahu7s%3D 10.1016/S0091-679X(10)95016-4 20466141
18. S Goel AC Mita M Mita, et al. 2009 A Phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid tumors Clin Cancer Res 15 4207 4212 1:CAS:528: DC%2BD1MXntlOisbY%3D 10.1158/1078-0432.CCR-08-2429 19509177
19. AR Tan EH Rubin DC Walton, et al. 2009 Phase I study of eribulin mesylate (E7389) administered once every 21 days in patients with advanced solid tumors Clin Cancer Res 15 4213 4218 1:CAS:528:DC%2BD1MXntlOisbc%3D 10.1158/1078-0432. CCR-09-0360 19509146
20. Synold TW, Morgan RJ, Newman EM, et al.: A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer consortium trial. J Clin Oncol 2005, 23:200 s (abstract).
21. Minami H, Mukohara T, Nagai S, Mukai H, Namiki M: A phase I study of eribulin mesylate (E7389) in patients with refractory cancers. Eur J Cancer Suppl 2008, 6:140 (abstract).
22. Vahdat LT, Pruitt B, Fabian CJ, et al.: Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009, 27:2954-2961. The first of the phase 2 clinical trials investigating safety and efficacy of eribulin in patients with MBC. This study focused upon patients pretreated with anthracycline and a taxane, and highlights for the first time a potential role for eribulin in the treatment of patients refractory to these conventional therapies.
23. Cortes J, Vahdat L, Blum JL, et al.: Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010, 28:3922-3928. The second phase 2 trial, this study supports previously reported findings of safety and efficacy of eribulin in heavily pretreated patients with MBC.
24. Iwata H, Aogi K, Masuda N, et al.: Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer. J Clin Oncol 2010, 28:1081. This phase 2 study demonstrated efficacy of eribulin in Japanese patients with MBC and reported similar findings that eribulin is well tolerated and efficacious in patients who have previously received chemotherapeutic regimens containing anthracycline and a taxane.
25. Twelves C, Loesch D, Blum JL, et al.: A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010, 28:CRA1004 (abstract). This is the first phase 3 clinical study of eribulin in patients with MBC who have been previously treated with an anthracycline or a taxane, compared to treatment of physician's choice. This trial is the first to date to establish a significant increase in overall survival for a monotherapy used in the late-line setting in heavily pretreated patients.
26. National Cancer Institute: Halichondrin analog. Available at http://www.dtp.nci.nih.gov/timeline/posters/Halichondrin.pdf. Accessed Feb 2009.
27. G Kuznetsov K TenDyke MJ Yu BA Littlefield 2007 Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro Proc Am Assoc Cancer Res 48 275
28. P Witteveen S Marchetti M Mergui-Roelvink, et al. 2010 Eribulin mesylate pharmacokinetics in patients with hepatic impairment J Clin Oncol 28 2582
29. Devriese LA, Wanders J, Jenner A et al.: Eribulin mesylate phamacokinetics in patients with solid tumors receiving repeated oral ketoconazole (KET). Abstract presented at the 22nd EORTC-AACR-NCI meeting, Berlin, Germany, November 16-19, 2010.
30. U Swami DP Petrylak H Raftopoulos, et al. 2010 Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors J Clin Oncol 28 2589